126 results on '"Kauh J"'
Search Results
2. A phase I study of HMPL-523, a selective oral anti-spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma
3. Safety and tolerability of surufatinib in western patients with solid tumours
4. A phase I study of HMPL-689, a selective oral phosphoinositide 3-kinase-delta inhibitor, in patients with relapsed or refractory lymphoma
5. Preliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers
6. A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB
7. Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy
8. 1393P - Safety and tolerability of surufatinib in western patients with solid tumours
9. 1106TiP - A phase I study of HMPL-523, a selective oral anti-spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma
10. 1107TiP - A phase I study of HMPL-689, a selective oral phosphoinositide 3-kinase-delta inhibitor, in patients with relapsed or refractory lymphoma
11. 1147P - Preliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers
12. 698P - A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB
13. Prospective open-label single center study of safety and efficacy of glass-based Y90 radioembolization for infiltrative HCC with PVT
14. Update with longitudinal analysis of quality of life assessment after doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE) in patients with hepatocellular carcinoma (HCC)
15. Longitudinal quality of life assessment of patients with hepatic metastatic colorectal adenocarcinoma after treatment with transarterial radioembolization Yttrium-90 therapy
16. Doxorubicin drug eluting beads transcatheter chemoembolization (DEB TACE) in patients with hepatocellular carcinoma (HCC): Survival outcomes and factors predicting survival outcomes in a 366-patient cohort
17. Survivals and predictive factors of metastatic hepatocellular carcinoma (MHCC) treated with doxorubicin drug eluting beads transcatheter chemoembolization (DEB TACE)
18. Survivals and predictive factors of atypical unresectable hepatocellular carcinoma (MHCC) treated with doxorubicin drug eluting beads transcatheter chemoembolization (DEB TACE)
19. Quality of life assessment after radiofrequency ablation (RFA) in patients with malignant liver tumors
20. The therapeutic dilemma of BCLC C hepatocellular carcinoma (HCC): an interventional oncology-based approach
21. Resin-based Yttrium-90 radioembolization for metastatic neuroendocrine tumors in a single-center cancer registry
22. A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies
23. Reirradiation for Cancers of the Rectum and Anal Canal
24. Abstract No. 219: Correlation of survival and tumor response with WHO, RECIST, EASL and mRECIST criteria after doxorubicin drug eluting beads transarterial chemoembolization (DEB TACE) in unresectable hepatocellular carcinoma (HCC)
25. Abstract No. 239: Magnetic resonance imaging biomarkers predicting survivals after doxorubicin drug eluting beads transarterial chemoembolization (DEB TACE) in patients with unresectable hepatocellular carcinoma (HCC)
26. 1210 POSTER Phase 1 Study of MLN9708, an Investigational Proteasome Inhibitor, in Advanced Nonhematologic Malignancies- Updated Results
27. MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules.
28. Abstract No. 244: Survival outcomes of doxorubicin drug eluting beads transcatheter chemoembolization (DEB TACE) for advanced hepatocellular carcinoma (HCC)
29. Abstract No. 207: Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: Survival, efficacy and safety study
30. Abstract No. 245: Survivals and predictive factors of metastatic hepatocellular carcinoma (MHCC) treated with doxorubicin drug eluting beads transcatheter chemoembolization (DEB TACE)
31. Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer.
32. Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.
33. Chemoembolization with doxorubicin drug-eluting beads for unresectable hepatocelluar carcinoma with portal vein thrombosis.
34. Phase IB dose escalation study of bortezomib and sunitinib in patients with refractory solid tumors.
35. Long-term survival after locoregional therapy in patients with unresectable hepatocellular carcinoma: Improvements over two decades.
36. Abstract No. 143: 100-300μM drug eluted bead with 100mg doxorubicin transcatheter chemoembolization for HCC; initial experience
37. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma
38. Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and skin
39. High-risk factors affecting survival after transcatheter therapy with doxorubicin-eluting beads for unresectable hepatocellular carcinoma
40. Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study
41. Locoregional therapies as a bridge to transplant in patients with hepatocellular carcinoma
42. Proportion of subjects with an ethically acceptable reason for enrolling in a phase I trial
43. Drug eluting beads versus conventional TACE for unresectable hepatocellular carcinoma: Survival benefits and safety
44. Single-fraction Image Guided Extracranial Radiosurgery for Recurrent and Metastatic Abdominal and Pelvic Cancers: Short-term Local Control, Metabolic Response and Toxicity
45. Single-fraction image-guided extracranial radiosurgery for recurrent and metastatic abdominal cancers: Short-term local control, metabolic response, and toxicity
46. Research participants’ views of nontherapeutic biopsies
47. Bortezomib (B) and doxorubicin (dox) in patients (pts) with hepatocellular cancer (HCC): A phase II trial of the Eastern Cooperative Oncology Group (ECOG 6202) with laboratory correlates
48. Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group’s Study E1203
49. Advanced pancreatic cancer: a multi-institutional trial with gemcitabine and thalidomide
50. AG879, a c-erbB2 tyrosine kinase inhibitor, causes G1 arrest in pancreas cancer cells through p27Kipl independent transcriptional repression of cyclin Dl
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.